Clinical trial
A Phase III, Open Label, Randomised，Controlled, Multi-centre Study to Assess the Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
NCT04409223 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Open Label, Randomised，Controlled, Multi-centre Study to Assess the Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- September 12, 2020
- Completion date
- March 25, 2022
- Enrollment
- 185 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.